Glycostem will join NK2022 to present posters on 15 May, 2022 during the POSTER SESSION I, in Florida, United States.

25  Universal prospects of cryopreserved “off-the-shelf” umbilical cord blood CD34+ progenitor cell-derived NK cell therapeutics: Clinical and preclinical evaluation of GTA002 and genetically modified candidates
Adil D. Duru, Glycostem Therapeutics B.V.

29  Multimodal activation of ex vivo expanded GTA002 NK cells efficiently targets melanoma
Amanda A. Van Vliet, Glycostem Therapeutics

100  Enabling treatment options against colorectal cancer by enhancing functionality of stem cell derived NK cells
Nina Lamers, PhD, Glycostem Therapeutics

Glycostem to present two poster presentations during ISCT 2022 at San Francisco, California, US.

The summit is now taking place till 7 May in San Francisco, US. Our Development Senior Scientist John Veluchamy, PhD is onsite to present the below posters:

Session 930
A FULLY AUTOMATED CD34+ CELLS ENRICHMENT FROM FRESH AND FROZEN UMBILICAL CORD BLOOD FOR CLINICAL SCALE MANUFACTURING OF NK CELLS USING A CLINIMACS PRODIGY PLATFORM

Session 931
A FULLY AUTOMATED NK CELL HARVEST PROCEDURE FOR CLINICAL SCALE MANUFACTURING OF NK CELLS USING A CLINIMACS PRODIGY PLATFORM

Glycostem is going to be present at the Lunch & Learn organized by Pivot Park, taking place on 12^th April 2022.

Glycostem CEO Troels Jordansen will share our uNiK™ closed manufacturing system of NK cells.

Glycostem CMO Kai Pinkernell and CDO Volker Huppert are going to attend the Innate Killer Summit 2022 in San Diego, US, from 30 March to 1 April, 2022.

31 March:
08:00 Chair’s Opening Remarks - - Kai Pinkernell
1 April:
08:45 Keynote speech: Examining Data from NK Cell Therapy to Assess Therapeutic Efficacy, and Preclinical Findings from CAR-NK Cells - Kai Pinkernell
11:00 Panel discussion: Examining Early Clinical Results & Translational Learnings - Kai Pinkernell
/11:00 Keynote speech: Conferring Stability, Consistency, and High Product Quality with Manufacturing at Scale - Volker Huppert
13:30 Panel discussion: Developing Commercial Strategy for Allogeneic Therapies - Kai Pinkernell

Glycostem CEO Troels Jordansen is going to participate the 4th Annual Cell & Gene Therapy Innovation Leaders Summit 2022, as keynote speaker, in Berlin, Germany.

Glycostem CEO Troels Jordansen and CMO Kai Pinkernell, MD, MBA to participate and give keynote speech at the Allogeneic Cell Therapies Summit Europe 2022 during 19^th-20^th January, 2022 in London, UK.

19^th Jan 2022

09:00-10:00 GMT: Keynote Panel: Achieving an Off-the-Shelf Future for Europe
17:00-17:30 GMT: Off-the-Shelf NK Cells in European AML Clinical Trial